ASCO 2023 | The emerging role of T-cell engagers in SCLC and neuroendocrine carcinomas

Martin Wermke, MD, University Hospital Carl Gustav Carus, Dresden, Germany, comments on the future of T-cell engagers in the management of small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC). Current clinical trials have assessed T-cell engagers in the second and third line setting, providing treatment alternatives to chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.